Breaching the Blood-Brain Barrier: Evolving Strategies for Central Nervous System Disease in Adult Acute Lymphoblastic Leukemia.
Modern leukemia treatments work better systemically, but careful brain-penetrating strategies prevent the disease from hiding in the nervous system where standard drugs can't reach.
This comprehensive evidence-based review from the University of Virginia addresses CNS disease management in adult ALL in the modern immunotherapy era, highlighting the paradox where blinatumomab and inotuzumab improve systemic control but CNS relapse is increasingly recognized, while CAR T-cell therapy demonstrates meaningful CNS activity. The authors provide an institutional framework covering diagnosis, risk stratification, prophylaxis, and treatment of CNS disease, emphasizing integration of rigorous intrathecal prophylaxis with novel agents capable of penetrating the CNS microenvironment.
What the study was
- Study design
- review
- Population
- Adult ALL patients receiving immunotherapy-era regimens
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Curr Hematol Malig Rep
Why it surfaced
Timely review in Current Hematologic Malignancy Reports addressing CNS disease in adult ALL (high unmet need); covers CAR-T, blinatumomab, inotuzumab implications; provides evidence-based institutional treatment algorithm; corrected from HIGH to STANDARD: score 7 with no HIGH-forcing flag.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.